Scientific News Health care Medicinal preparations PAIN IN THE GUT? DON'T BLAME STOMACH ACID. U-M SCIENTISTS SHOW WHY INHIBITING ACID PRODUCTION COULD MAKE GASTRITIS WORSE.
PAIN IN THE
GUT?
DON'T BLAME STOMACH ACID. U-M SCIENTISTS SHOW WHY INHIBITING ACID PRODUCTION
COULD MAKE GASTRITIS WORSE.
When it comes to cooling the burning pain of
gastritis or an inflamed stomach lining, reducing the amount of acid in the
stomach may seem like a good idea. But two new studies with laboratory mice,
conducted by Howard Hughes Medical Institute scientists at the University of
Michigan Medical School, indicate it could be exactly the wrong thing to do.
U-M scientists found that antibiotics were the
best way to kill the bacteria that cause gastritis and eliminate stomach
inflammation in their experimental mice. Mice treated with prescription drugs
called proton pump inhibitors or PPIs, which block acid production, acquired
more bacteria and developed more inflammatory changes in their stomach linings
than untreated mice.
"These animal studies indicate that it is
the inflammatory response - triggering the overproduction of hydrochloric acid -
which is the stomach's primary response to bacterial colonization," says
Juanita L. Merchant, M.D., Ph.D., an HHMI assistant investigator and U-M
associate professor of internal medicine and physiology. "Inflammation of
the stomach lining coincides with production of peptides called cytokines, which
stimulate production of a hormone called gastrin. Gastrin triggers parietal
cells in the stomach lining to produce more hydrochloric acid, which kills off
most invading microbes. If you inhibit gastric acid production, you interfere
with the stomach's natural defense mechanism."
Merchant cautions that without controlled
clinical trials, it is impossible to know whether the results would be exactly
the same in humans. She also emphasizes that a type of bacteria called
Helicobacter pylori, the most common cause of gastritis, was excluded from these
studies. Since reduced gastric acidity does appear to make the mammalian stomach
more vulnerable to bacterial invasion and gastritis, however, Merchant says
physicians may want to re-evaluate the long-term use of omeprazole and other
proton-pump-inhibiting drugs in their patients.
Together with Yana Zavros, Ph.D., an HHMI
post-doctoral fellow, Merchant and colleagues compared stomach cells from normal
mice with those from a strain of transgenic mice, developed at U-M, that lack
the gene for producing gastrin. Their goal was to understand the feedback
relationship between bacteria, pro-inflammatory factors, hormones and acid
secretion in the stomach. Results are published in the January 2002 issues of
Gastroenterology and The American Journal of Physiology.
Mice in the U-M studies contracted gastritis just
like people do - from eating food or drinking water contaminated with bacteria.
While 75 percent of people with gastritis test positive for Helicobacter pylori,
many other species of bacteria can trigger inflammatory changes, too, and often
co-exist with Helicobacter. No matter what type of bacteria causes the problem,
it is a serious medical condition. If untreated, chronic gastritis can lead to
peptic ulcers and stomach cancer.
H. pylori is the only bacterial organism in the
stomach that cannot be killed by hydrochloric acid. Since Merchant wanted to
study the relationship between other bacteria and gastric acid, she needed to
exclude the presence of H. pylori. U-M scientists cultured and analyzed bacteria
from stomach washings of all normal and gastrin-deficient mice to confirm the
absence of Helicobacter. Major types of bacteria identified included
Lactobacillus, Enterobacter and Staphylococcus.
U-M scientists treated infected gastrin-deficient
mice and normal control mice with antibiotics for 20 days. Other mice were
treated for two months with a proton-pump-inhibiting drug called omeprazole or
with a combination of omeprazole and antibiotics. At the end of the treatment
period, researchers compared cell changes and bacterial counts from the stomach
linings of all mice.
Major findings from the U-M studies include:
- Stomach cell samples from both the transgenic
gastrin-deficient mice and the normal mice whose ability to produce gastric
acid was inhibited by omeprazole all showed significant inflammatory changes
-- including more immune cells called lymphocytes -- and greater numbers of
bacteria.
- Gastritis that developed in mice on omeprazole
resolved after 20 days of antibiotic treatment, despite continued omeprazole
treatment and low stomach acidity.
- The number of acid-producing parietal cells
and gastrin-secreting G-cells in the stomach increased in all mice with
abnormally low levels of hydrochloric acid. Elevated numbers of parietal and
G-cells correlated with the presence of inflammation, not with stomach
acidity.
- Elevated levels of gastrin during chronic
inflammation suppressed production of a growth hormone called somatostatin,
which inhibits parietal and G-cell function. When the inflammation subsided
following antibiotic treatment, gastrin levels returned to normal releasing
the hormonal brake inhibiting somatostatin.
"Our findings show that changes observed in
gastrin-deficient mice are caused by inflammation triggered by an overgrowth of
many bacterial species," Zavros explains. "An abnormally low level of
acidity in the stomach is the factor initiating all these events."
"The bottom-line message is that a two-week
course of antibiotics to treat the inflammation is essential for a successful
cure," Merchant adds. "Once you get rid of the inflammation, the
gastric acid levels should return to normal. It is crucial to take antibiotics
for the entire two weeks exactly as your physician has prescribed, however.
People often stop taking their medication early or skip doses, which helps the
bacteria to develop antibiotic resistance."
###
In addition to the Howard Hughes Medical
Institute, this research was supported by the National Institutes of Health.
Linda C. Samuelson, Ph.D., an associate professor of physiology in the Medical
School, developed the strain of transgenic mice used in the experiments. Former
U-M post-doctoral fellows Gabriele Rieder, Ph.D., and Amy Ferguson, Ph.D.,
collaborated in the study.
Gastroenterology 122:119-133, 2002 - V text
available at: http://www.gastrojournal.org/cgi/content/full/122/1/119
Am J Physiol Gastrointest Liver Physiol
282:G175-G183, 2002
A press release from the Howard Hughes Medical
Institute is available at http://www.hhmi.org/
Contact: Sally Pobojewski, pobo@umich.edu,
734-615-6912, University
of Michigan Health System
Source of the given news and the copyrights
belong to a University
of Michigan Health System
Publishing date: January 23, 2002
Back
|